1Rivera MP. Muhimodality therapy in the treatment of lung cancer [J]. Semin Respir Crit Care Med, 2004, 25 (2): 395-401.
2Le Chevalier T, Lynch T. Adjuvant treatment of lung cancer: current status and potential applications of new regimens [ J]. Lung Cancer, 2004, 46 (suppl2): 33-39.
3Martel MK, Ten Haten RK, Hazuka MB, et al. Estimation of tumor control probability model parameters from 32d dose distributions of non-small-cell lung cancer patients [ J ]. Lung Cancer, 1999, 24 (1): 31-37.
4Hayman JA, Martel MK, Ten Haken R, et al. Dose escalation in non-small-cell lung cancer using three dimensional conformal radiation therapy: update of a phase I trial [J]. J Clin Oncol, 2001, 19 (2): 127-136.
5Belderbos JS, Jaeger KD, Heemsbergen WD, et al. First results of a phase Ⅰ / Ⅱ dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy [ J ]. Radiother Oncol, 2003, 66 (2): 119-126.
6Senan S, Burgers S, Samson MJ, et al. Can elective nodal irradiation be omitted in stage Ⅲ non-small-cell lung cancer? Analysis of recurrences in a phase Ⅱ study of induction chemotherapy and involved field radio-therapy [ J ]. Int J Radiat Oncol Biol Phys, 2002, 54 (11): 999-1006.
7Liao Z, Komaki R, Stevens C, et al. Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage Ⅱ -Ⅲ B non-small-cell lung cancer [J]. Int J Radiat Oncol Biol Phys, 2002, 53 (6): 558-565.
8Ruysscher DD, Wanders S, Haren EV, et al. Selective mediastinal node irradiation on basis of the FDG-PET scan in patients with NSCLC is safe: results of a prospective clinical study [J]. ESTRO, 2004, 23: 143-144.
9Caldwell CB, Mah K, Skinner M, et al. Can PET provide the 3D extent of tumor motion for individualized internal target volumes? A phantom study of the limitations of CT and the promise of PET [J]. Int J Radiat Oncol Biol Phys, 2003, 55 (11): 1381 - 1393.
10Pisch J, Mo skovitz T, Esik O, et al. Concurrent paclitaxel-cisplatin and twice-a-day irradiation in stage IliA and IIIB NSCLC shows improvement in local control and survival with acceptable hematologic toxicity [J]. Pathol Oncol Res, 2002, 8 (3): 163- 169.
